ZyVersa Therapeutics, Inc.
ZVSA· OTC
ZVSAZyVersa Therapeutics, Inc.
Filed Aug 9, 2024 · 10-Q · 40 days after period end · 0001493152-24-031002
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$2.76M | -$78.51M | -$393.64K | -$1.90K |
| EPS Diluted | -$3.31 | -$1,694.12 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end
